Sugi Predict

Sugi Predict / Compounds / SCHEMBL2017499

SCHEMBL2017499

SCHEMBL2017499

COC(=O)Cc1ccnc(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOX P28300 1/20 0.57
▸ LOXL2 Q9Y4K0 1/20 0.57
▸ ALDH1A1 P00352 2/20 0.47
▸ GAA P10253 1/20 0.47
▸ GFER P55789 1/20 0.47
▸ HSP90AB1 P08238 1/20 0.47
▸ CYP4F2 P78329 1/20 0.45
▸ CYP4A11 Q02928 1/20 0.45
▸ FFAR1 O14842 1/20 0.44
▸ WNT3A P56704 2/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ ACACB O00763 1/20 0.42
▸ SLC7A5 Q01650 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CDK2 P24941 2/20 0.42
▸ CCNE1 P24864 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30184846 1.00 LOX (0.57) LOXLOXL2ALDH1A1GAAGFER
SCHEMBL30088474 0.86 LOX (0.53) LOXLOXL2ALDH1A1FFAR1CDK2
SCHEMBL16108961 0.86 LOX (0.53) LOXLOXL2ALDH1A1FFAR1CDK2
SCHEMBL5510542 0.85 LOXL2 (0.59) LOXLOXL2ALDH1A1FFAR1WNT3A
SCHEMBL31280150 0.85 LOXL2 (0.59) LOXLOXL2ALDH1A1GAAFFAR1
SCHEMBL22286716 0.85 LOXL2 (0.59) LOXLOXL2ALDH1A1GAAFFAR1
SCHEMBL9103236 0.84 LOX (0.54) LOXLOXL2FFAR1ACACBSYK
SCHEMBL29919922 0.83 ALDH1A1 (0.47) ALDH1A1GAAGFERHSP90AB1CYP4F2
SCHEMBL16797558 0.83 ALDH1A1 (0.47) ALDH1A1GAAGFERHSP90AB1CYP4F2
SCHEMBL30361238 0.83 LOXL2 (0.62) LOXLOXL2FFAR1WNT3ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734977-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF Neucures, Inc. (US) 2026-05-06 — — EP disclosed
US-20250215029-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 — — US disclosed
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. 2025-06-05 — — US disclosed
WO-2025006675-A9 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-03-13 — — WO disclosed
WO-2025006675-A2 NOVEL TRPV1 AGONISTS AND USES THEREOF NEUCURES, INC. (US) 2025-01-02 — — WO disclosed
EP-4463459-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2024-11-20 — — EP disclosed
WO-2023164680-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS RECLUDIX PHARMA, INC. (US) 2023-08-31 — — WO disclosed
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof Suzhou Alphama Biotechnology Co., Ltd. (CN) 2023-07-13 — — US disclosed
WO-2023133336-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-07-13 — — WO disclosed
CN-115340555-A Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2022-11-15 — — CN disclosed
US-8541592-B2 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 AMGEN INC. (US) 2013-09-24 — — US disclosed
US-7956060-B2 Pyrimidine derivative compound KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-06-07 — — US disclosed
US-20090012060-A1 Antitumor Agent KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-01-08 — — US disclosed
EP-1951696-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 Amgen Inc. (US) 2008-08-06 — — EP disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 — — US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 — — US disclosed
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 AMGEN INC. 2007-08-23 — — US disclosed
WO-2007061661-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2007-05-31 — — WO disclosed
WO-2007061661-A2 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 AMGEN INC. (US) 2007-05-31 — — WO disclosed
EP-1749827-A1 ANTI-TUMOR AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250179103-A1 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS STAT6, STAT3, STAT1 LOX 433/4885LOXL2 1851/4885ALDH1A1 531/4885
US-20090012060-A1 Antitumor Agent NR1H3, NR1I3, NR0B1 LOX 3493/4885LOXL2 3297/4885ALDH1A1 1834/4885
US-20250215029-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A LOX 2571/4885LOXL2 2929/4885ALDH1A1 2707/4885
US-20230219961-A1 Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof CDK9, CDK7, CDK8 LOX 2078/4885LOXL2 1834/4885ALDH1A1 1645/4885
US-20070197598-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 LOX 2753/4885LOXL2 3750/4885ALDH1A1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.